Log in to your Inderes Free account to see all free content on this page.
BICO Group
44.46 SEK +0.32%2 investors are following this company
BICO Group is active in medical technology. The company specializes in bio convergence and provides technology, products, and services for biology. With a focus on the application areas bioprinting, multi-omics, cell line development, and diagnostics, the company develops and markets technology that enables researchers to grow cells in 3D environments, conduct drug screening, and print human tissues and organs for the medical, pharmaceutical, and cosmetic industries.
Revenue
2.25B
EBIT %
-64.44 %
P/E
-
Dividend yield-%
-
Target price
-
Recommendation
-
Updated
-
NASDAQ Stockholm
BICO
Daily low / high price
43.68 / 44.8
SEK
Market cap
3.14B SEK
Turnover
2.65M SEK
Volume
60K
Latest videos
Financial calendar
Interim report
20.08.2024
Interim report
13.11.2024
Annual report
19.02.2025
Major OwnersSource: Millistream Market Data AB
Owner | Capital | Votes |
---|---|---|
Erik Gatenholm | 13.6 % | 20.5 % |
Sartorius Lab Holding GmbH | 10.1 % | 8.5 % |
Premium
This content is for our Premium customers only.
ShowingAll content types
BICO publishes adjusted Annual and Sustainability Report 2023
![BICO, Audiocast with teleconference, Q1, 2024](https://www.inderes.se/cdn-cgi/image/format=auto,width=640,height=358,quality=90,fit=cover/https://content.inderes.se/assets/e0ae8192-bd99-4224-a6cd-569d585ff682.png)
BICO, Audiocast with teleconference, Q1, 2024
Join Inderes community
Don't miss out - create an account and get all the possible benefits
FREE account
Stock market's most popular morning newsletter
Analyst comments and recommendations
Stock comparison tool
PREMIUM account
All company reports and content
Premium tools (e.g. insider transactions & stock screener)
Model portfolio
Publication of BICO Group Interim report January-March 2024
BICO changes method for impairment test of goodwill resulting in retroactive impairment of goodwill for 2022 and 2023 and provides preliminary figures for Q1 2024
Invitation to the presentation of BICO’s interim report Q1, 2024
Anders Fogelberg appointed as Chief Commercial Officer for BICO Group AB (publ)
Notice to attend the Annual General Meeting in BICO Group AB (publ)
Founders leave after eight years
BICO Publishes Annual and Sustainability Report 2023
![BICO, Audiocast with teleconference, Q4, 2023](https://www.inderes.se/cdn-cgi/image/format=auto,width=640,height=358,quality=90,fit=cover/https://content.inderes.se/assets/46a00eef-72f4-439f-b728-929e0070887e.png)
BICO, Audiocast with teleconference, Q4, 2023
Publication of BICO Group Year-end report 2023
BICO announces goodwill impairment of SEK 582m and provides preliminary figures for Q4 2023
Invitation to the presentation of BICO’s interim report Q4, 2023
Catharina Nordlund is appointed Global Head of HR for BICO Group AB (publ)
BICO company Biosero has signed an agreement to develop laboratory automation solutions to a value of 28 MUSD
BICO has completed the divestment of the Berlin property for a total of EUR 21m
![BICO, Audiocast with teleconference, Q3, 2023](https://www.inderes.se/cdn-cgi/image/format=auto,width=640,height=358,quality=90,fit=cover/https://content.inderes.se/assets/34f338c7-c628-462a-9e0b-e284586ea778.png)